ASCO GU 2019: First-line Pembrolizumab Monotherapy for Advanced Non-Clear Cell Renal Cell Carcinoma: Results from KEYNOTE-427 Cohort B

Keynote 427 Cohort B results demonstrate promising anti-tumor activity with first line pembrolizumab monotherapy in non-clear cell advanced RCC.02/19/2019
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news